{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:58:13Z","timestamp":1773392293315,"version":"3.50.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13760-025-02781-4","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T05:46:49Z","timestamp":1743832009000},"page":"269-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acta neurologica belgica regarding the manuscript entitled \u2018Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis\u2019"],"prefix":"10.1007","volume":"126","author":[{"given":"Mike","family":"Boggild","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinat","family":"Mohammadpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lachlan","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"2781_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s13760-024-02480-6","volume":"124","author":"EM Rabea","year":"2024","unstructured":"Rabea EM, Belal MM, Hafez AH et al (2024) Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis. Acta Neurol Belg 124:407\u2013417","journal-title":"Acta Neurol Belg"},{"key":"2781_CR2","doi-asserted-by":"crossref","unstructured":"Deeks JJ, Higgins JP, Altman DG et al (2019) Analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions. 241\u2013284","DOI":"10.1002\/9781119536604.ch10"},{"key":"2781_CR3","doi-asserted-by":"publisher","first-page":"175628642110424","DOI":"10.1177\/17562864211042458","volume":"14","author":"H Butzkueven","year":"2019","unstructured":"Butzkueven H, Kappos L, Spelman T et al (2019) No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score\u2013matched comparison with every-4-week dosing in patients enrolled in the Tysabri observational program (TOP). Ther Adv Neurol Disord 14:17562864211042458","journal-title":"Ther Adv Neurol Disord"},{"key":"2781_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","volume":"21","author":"JF Foley","year":"2022","unstructured":"Foley JF, Defer G, Ryerson LZ et al (2022) Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol 21:608\u2013619","journal-title":"Lancet Neurol"},{"key":"2781_CR5","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","volume":"93","author":"LZ Ryerson","year":"2019","unstructured":"Ryerson LZ, Foley J, Chang I et al (2019) Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93:e1452\u2013e1462","journal-title":"Neurology"},{"key":"2781_CR6","doi-asserted-by":"publisher","unstructured":"Ryerson LZ, Foley J, Kister I et al (2024) Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) with Natalizumab Extended Interval Dosing (EID) Compared with Every-4-week (Q4W) Dosing: Updated Analysis of the TOUCH\u00ae Prescribing Program Database (P10-6.005). Neurology https:\/\/doi.org\/10.1212\/WNL.0000000000204375","DOI":"10.1212\/WNL.0000000000204375"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02781-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-025-02781-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02781-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:54:31Z","timestamp":1773384871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-025-02781-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2781"],"URL":"https:\/\/doi.org\/10.1007\/s13760-025-02781-4","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}